Virtual Biotech runs 37,075 parallel AI agents across 11 scientist roles to scale drug discovery
bravo_abad · x · 2026-09-19
Jorge Bravo-Abad's AI-for-Science newsletter Discovery at Scale spotlights Virtual Biotech, which uses 11 AI scientist roles and 37,075 parallel agents to run drug discovery like a research organization.
The core argument: a single AI agent with access to every database sounds powerful, but scientific problems quickly outgrow one context window, one toolset, and one line of reasoning. Instead, Virtual Biotech copies the division of labor of a real research org — a virtual CSO coordinates specialized roles — turning discovery into a parallelized, organizational workflow.
The post doubles as promotion for the paid Substack; full method details are behind the original piece.
More from Research
- JevBench v1 puts nine typed-decision models head-to-head across 242 decisions — airesearch12 · 2026-09-19
- FlashREINFORCE debuts: critic-free, single-rollout async RL for agentic LLMs — CatAstro_Piyush · 2026-09-19
- AI companies are conquering math — and exposing a discipline built on competition, not understanding — danbri · 2026-09-19
- CMU Autonomous Science Lab to Feature at Enamine Drug Discovery Conference — olexandr · 2026-09-19
- AI & Science feature in Scientific American gets a positive write-up — JMateosGarcia · 2026-09-19
- Terence Tao: If Math Is More Than Proof, We Must Celebrate the Rest of It — num42 · 2026-09-19